News & Events about Vertex Pharmaceuticals Incorporated.
InvestorPlace
9 months ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025
The post 3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025 appeared first on ...
Business Wire
9 months ago
Vertex Pharmaceuticals today announced that the European Commission has granted approval for the label extension of ORKAMBI (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) ages 1 to <2 years old who have two copies of the F508del mutation in the cystic fibrosis...
Business Wire
10 months ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2023 financial results on Tuesday, August 1, 2023 after the financial markets close. The company will host a...
Ticker Report
10 months ago
Vertex Pharmaceuticals (NASDAQ:VRTX Get Rating) had its price target hoisted by Royal Bank of Canada from $315.00 to $323.00 in a research report sent to investors on Thursday, The Fly reports. Other analysts have also issued reports about the stock. SVB Securities lowered their price ...
Business Wire
10 months ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary...